Risperidone in the treatment of Tourette syndrome: a retrospective case note study.

Abstract

Nineteen patients with Tourette syndrome (TS) were treated with risperidone, at a mean daily dose of 1.5 mg. Of those, 41% responded positively, 35% felt that it had made no difference, while it made 24% worse. Although 53% of the patients experienced side-effects, none had extrapyramidal side-effects. At follow-up, 8 to 11 months later, only two of 19 (11 %) patients were still taking risperidone. We suggest that risperidone does have a role in a minority of TS sufferers but it is not suggested as the first line treatment. More placebo-controlled studies using risperidone are clearly indicated.

• Authors: M M Robertson, D A Scull, V Eapen, M R Trimble
• Journal: Journal of psychopharmacology (Oxford, England) (J Psychopharmacol) Vol. 10 Issue 4 Pg. 317-20 (Jan 1996) ISSN: 0269-8811 [Print] United States
• PMID: 22302981 (Publication Type: Journal Article)